Advancing Cancer Immunotherapy: From Molecular Mechanisms to Clinical Applications.

In recent years, cancer immunotherapy research has made remarkable progress, completely transforming the cancer treatment landscape [...].

[1]  P. Lizotte,et al.  Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells , 2023, Cancers.

[2]  M. Aghi,et al.  Metabolic Barriers to Glioblastoma Immunotherapy , 2023, Cancers.

[3]  J. Gumin,et al.  A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin , 2023, Cancers.

[4]  C. Stolfi,et al.  Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance , 2023, Cancers.

[5]  A. Rasmusson,et al.  CD8+ Cell Density Gradient across the Tumor Epithelium–Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy , 2023, Cancers.

[6]  Sander Bekeschus,et al.  Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models , 2023, Cancers.

[7]  Yusheng Chen,et al.  Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures , 2023, Cancers.

[8]  Subbaya Subramanian,et al.  Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. , 2022, Pharmacology & therapeutics.

[9]  P. Krawczyk,et al.  Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients , 2022, Cancers.

[10]  H. Lode,et al.  The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta , 2022, Cancers.

[11]  Zhiyi Chen,et al.  Recent Advances in Bacteria-Based Cancer Treatment , 2022, Cancers.

[12]  T-G Huang,et al.  Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor , 2022, Cancers.

[13]  A. Colao,et al.  Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? , 2022, Cancers.

[14]  Subbaya Subramanian,et al.  Cancer Immunology and Immunotherapies: Mechanisms That Affect Antitumor Immune Response and Treatment Resistance , 2021, Cancers.

[15]  G. Behbehani,et al.  A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma , 2020, Cancers.

[16]  Subbaya Subramanian,et al.  Acquired Resistance to Immune Checkpoint Blockade Therapies , 2020, Cancers.

[17]  Subbaya Subramanian,et al.  Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. , 2017, Cancer research.

[18]  Subbaya Subramanian,et al.  Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy , 2018, Pharmacology & therapeutics.